Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer

被引：0
|
作者：
Wen Ouyang
Jing Yu
Yan Zhou
Jing Hu
Zhao huang
Junhong Zhang
Conghua Xie
机构：
[1] Zhongnan Hospital of Wuhan University,Department of Radiation and Medical Oncology
[2] Zhongnan Hospital of Wuhan University,Hubei Key Laboratory of Tumor Biological Behaviors
[3] Zhongnan Hospital of Wuhan University,Hubei Clinical Cancer Study Center
来源：
BMC Cancer | / 20卷
关键词：
Non-small cell lung cancer; Epidermal growth factor receptor; Brain metastases; Risk factor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Early dose reduction of osimertinib in advanced EGFR-mutated non-small cell lung cancer
    Ferreira, Marion
    Ebia, Matthew I.
    Reckamp, Karen L.
    [J]. ANTI-CANCER DRUGS, 2024, 35 (07) : 672 - 679
  • [22] A Single-Institution Experience of Afatinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
    Minemura, Hiroyuki
    Yokouchi, Hiroshi
    Hirai, Kenichiro
    Koizumi, Tatsuhiko
    Kanazawa, Kenya
    Tanino, Yoshinori
    Munakata, Mitsuru
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1230 - S1231
  • [23] Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?
    Leonetti, Alessandro
    Facchinetti, Francesco
    Tiseo, Marcello
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
  • [24] Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
    Yuta Nio
    Hiroo Ishida
    Natsumi Matsumoto
    Sojiro Kusumoto
    Yutaro Kubota
    Takuya Tsunoda
    Yasutsuna Sasaki
    Ken-ichi Fujita
    [J]. BMC Pulmonary Medicine, 22
  • [25] Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
    Nio, Yuta
    Ishida, Hiroo
    Matsumoto, Natsumi
    Kusumoto, Sojiro
    Kubota, Yutaro
    Tsunoda, Takuya
    Sasaki, Yasutsuna
    Fujita, Ken-ichi
    [J]. BMC PULMONARY MEDICINE, 2022, 22 (01)
  • [26] Effectiveness of osimertinib plus chemotherapy and avastin for EGFR-mutated advanced non-small cell lung cancer with brain metastases
    Qin, H.
    Wang, S.
    Gao, F.
    Zeng, Z.
    Liu, X.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S967 - S967
  • [27] EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib
    Buder, Anna
    Hochmair, Maximilian J.
    Setinek, Ulrike
    Pirker, Robert
    Filipits, Martin
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (02) : 239 - +
  • [28] Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis
    Kuiper, Justine L.
    Hendriks, Lizza E.
    van der Wekken, Anthonie J.
    de Langen, Adrianus J.
    Bahce, Idris
    Thunnissen, Erik
    Heideman, Danielle A. M.
    Berk, Yvonne
    Buijs, Ed J. M.
    Speel, Ernst-Jan M.
    Krouwels, Frans H.
    Smit, Hans J. M.
    Groen, Harry J. M.
    Dingemans, Anne-Marie C.
    Smit, Egbert F.
    [J]. LUNG CANCER, 2015, 89 (03) : 255 - 261
  • [29] Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
    Mambetsariev, Isa
    Arvanitis, Leonidas
    Fricke, Jeremy
    Pharaon, Rebecca
    Baroz, Angel R.
    Afkhami, Michelle
    Koczywas, Marianna
    Massarelli, Erminia
    Salgia, Ravi
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (05)
  • [30] Leptomeningeal carcinomatosis from EGFR-mutated non-small cell lung cancer
    Iuchi, T.
    Shingyoji, M.
    Setoguchi, T.
    Yoshida, Y.
    Ashinuma, H.
    Hasegawa, Y.
    Sakaida, T.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
12345